All Clinical Trials

Clinical Trial NCT04589650

EPIK-P2: A Phase II double-blind study with an upfront, 16- week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

  • ClinicalTrials.gov ID: NCT04589650
  • Recruiting participants (Starts Jun. 28, 2021)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: KATHLEEN FAYE LUDWIG

summary

nada!

objective

draft

If you are interested in this clinical trial, please contact Caitlyn Ambrose on the Children’s Health Research Team.Call 214-456-2162Email